FBRX

Forte Biosciences Inc

Tocagen Inc is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient\'s immune system against cancer from within. Its pipeline product includes Toca 511 and Toca FC.

Forte Biosciences Inc (FBRX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -18.9
EV / EBITDA -18.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue N/A
Price / Sales N/A
ROE -62.3%

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) C- (2.0) D (1.3) C+ (2.5) C+ (2.6) C (2.2)
2026-11-04 C+ (2.5) C- (1.9) D (1.3) C+ (2.5) C+ (2.7) C (2.2)
2026-10-28 C+ (2.5) C- (1.9) D (1.3) C+ (2.5) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) C- (1.9) D (1.3) C+ (2.5) F (0.0) D+ (1.7)
2026-10-14 C+ (2.5) C- (1.9) D (1.3) C+ (2.5) F (0.0) D+ (1.7)
Page 1 of 4